Hutchinson Capital Managementca Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Hutchinson Capital Managementca reduced its stake in Pfizer by 1.16% during the most recent quarter end. The investment management company now holds a total of 57,117 shares of Pfizer which is valued at $2,015,659 after selling 668 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Pfizer makes up approximately 0.60% of Hutchinson Capital Managementca’s portfolio.

Other Hedge Funds, Including , Stelac Advisory Services added PFE to its portfolio by purchasing 3,119 company shares during the most recent quarter which is valued at $110,070. Pfizer makes up approx 0.03% of Stelac Advisory Services’s portfolio.Trillium Asset Management reduced its stake in PFE by selling 728 shares or 4.96% in the most recent quarter. The Hedge Fund company now holds 13,953 shares of PFE which is valued at $514,726. Pfizer makes up approx 0.03% of Trillium Asset Management’s portfolio.Princeton Capital Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 11,517 additional shares and now holds a total of 89,736 shares of Pfizer which is valued at $3,306,772. Pfizer makes up approx 2.15% of Princeton Capital Management Inc’s portfolio. Fox Run Management L.l.c. added PFE to its portfolio by purchasing 18,800 company shares during the most recent quarter which is valued at $689,584. Pfizer makes up approx 0.32% of Fox Run Management L.l.c.’s portfolio.

Pfizer closed down -0.14 points or -0.40% at $35.15 with 2,51,25,802 shares getting traded on Thursday. Post opening the session at $35.5, the shares hit an intraday low of $35.15 and an intraday high of $35.52 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.